{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:02:12Z","timestamp":1780426932271,"version":"3.54.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2023YFC3605500"],"award-info":[{"award-number":["2023YFC3605500"]}]},{"name":"National Key Research and Development Program of China","award":["2023YFC3605501"],"award-info":[{"award-number":["2023YFC3605501"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,26]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a form of necrotizing vasculitis not mediated by immune complexes, affecting multiple organs. The disease is particularly dangerous in its active stage, with high morbidity and mortality rates, especially among older patients. This study provides a possible treatment for ANCA in the elderly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>An 84-year-old man developed an intermittent cough of unknown etiology in early February 2024, accompanied by hemoptysis, sore throat, dry mouth, arthralgia, fatigue, and occasional low fever. He had a history of chronic kidney disease for over 14 years and had been diagnosed with AAV and ANCA-associated nephritis for more than 9 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Laboratory tests in the rheumatology department revealed C-ANCA positivity, proteinase 3\u2005&gt;\u2005200 RU\/mL, and an ANCA\u2005+\u2005proteinase 3 antibody concentration of 2300\u2005IU\/L. Serum creatinine concentration had increased to 457\u2005\u03bcmol\/L\u2191. Other autoantibodies, including anti-extra nuclear antigen, were negative. Based on these findings and the patient\u2019s clinical symptoms, the diagnosis of ANCA-associated vasculitis was confirmed. Imaging revealed patchy and reticular opacities in both lungs, with a butterfly-wing distribution along the hila, accompanied by a small amount of bilateral pleural effusion. Scattered petechiae were observed on both upper limbs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient\u2019s condition was critical and rapidly progressing. He received successive treatments, including methylprednisolone sodium succinate\u2005+\u2005cyclophosphamide, plasma exchange, blood purification, and repeated small-dose courses of rituximab and belimumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After 6 months of treatment, the patient achieved clinical, radiological, and serological remission. Hemoptysis stopped, renal function improved, immune status returned to normal, and there was no sign of ANCA recurrence. He was successfully discharged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Rituximab offers a promising therapeutic option for older patients with chronic kidney disease complicated by AAV. Multiple small-dose rituximab regimens may reduce drug-related side effects, significantly lower treatment costs, and provide an effective, economically viable approach for clinical management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044822","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:01:43Z","timestamp":1759248103000},"page":"e44822","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Plasma exchange combined with low-dose rituximab treatment: A case report of severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in the elderly"],"prefix":"10.1097","volume":"104","author":[{"given":"Zhiying","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Second Medical Center of Chinese PLA General Hospital, National Clinical Research Centre for Geriatric Diseases, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Medical Center of Chinese PLA General Hospital, National Clinical Research Centre for Geriatric Diseases, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bokai","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Medical Center of Chinese PLA General Hospital, National Clinical Research Centre for Geriatric Diseases, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Medical Center of Chinese PLA General Hospital, National Clinical Research Centre for Geriatric Diseases, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7000-0789","authenticated-orcid":false,"given":"Qiangguo","family":"Ao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Medical Center of Chinese PLA General Hospital, National Clinical Research Centre for Geriatric Diseases, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260602","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis.","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20260602","doi-asserted-by":"crossref","first-page":"e050507","DOI":"10.1136\/bmjopen-2021-050507","article-title":"Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review.","volume":"12","author":"Xiao","year":"2022","journal-title":"BMJ open"},{"key":"R3-20260602","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis.","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet (London, England)"},{"key":"R4-20260602","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11926-017-0632-1","article-title":"Rituximab in ANCA-associated vasculitis.","volume":"19","author":"Hassan","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"R5-20260602","first-page":"2261","article-title":"Perspective on the first-line induction therapy of rituximab for severe ANCA-associated vasculitis.","volume":"105","author":"Haijun","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"R6-20260602","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10067-019-04443-2","article-title":"Low-dose rituximab as induction therapy for ANCA-associated vasculitis.","volume":"38","author":"Takakuwa","year":"2019","journal-title":"Clin Rheumatol"},{"key":"R7-20260602","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.","volume":"83","author":"Geetha","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R8-20260602","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ard-2023-224623","article-title":"Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.","volume":"83","author":"Delestre","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R9-20260602","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00393-024-01548-1","article-title":"Therapie-Update der ANCA-assoziierten Vaskulitiden.","volume":"83","author":"Holle","year":"2024","journal-title":"Z Rheumatol"},{"key":"R10-20260602","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/bjh.19825","article-title":"Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.","volume":"205","author":"Moriguchi","year":"2024","journal-title":"Br J Haematol"},{"key":"R11-20260602","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral Blood B Cell depletion after rituximab and complete response in lupus nephritis.","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R12-20260602","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3899\/jrheum.170226","article-title":"Longterm data on disease flares in patients with proliferative lupus nephritis in recent years.","volume":"44","author":"Yap","year":"2017","journal-title":"J Rheumatol"},{"key":"R13-20260602","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0961203319829827","article-title":"Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study.","volume":"28","author":"Ichinose","year":"2019","journal-title":"Lupus"},{"key":"R14-20260602","doi-asserted-by":"crossref","first-page":"e064597","DOI":"10.1136\/bmj-2021-064597","article-title":"Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.","volume":"376","author":"Zeng","year":"2022","journal-title":"Bmj"},{"key":"R15-20260602","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-Associated Vasculitis.","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"R16-20260602","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial.","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"R17-20260602","first-page":"603","article-title":"Chinese guidelines for the diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.","volume":"37","year":"2021","journal-title":"Chin J Nephrol"},{"key":"R18-20260602","doi-asserted-by":"crossref","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis.","volume":"376","author":"Walsh","year":"2022","journal-title":"Bmj"},{"key":"R19-20260602","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/ndt\/gfac320","article-title":"Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis.","volume":"38","author":"S\u00e1nchez \u00c1lamo","year":"2023","journal-title":"Nephrol Dialysis Transplant"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:02:22Z","timestamp":1780423342000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":19,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044822","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}